secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001214659-26-002932
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital
--------------------------------------------------------------------------------

- Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.
- Sales occur under effective shelf registration statement (Form S-3, File No. 333-273610) from August 2023.
- Company controls timing, price, and volume; agent uses commercially reasonable efforts with no minimum commitment.
- Common stock trades on Nasdaq under ALZN; shares sold will be freely tradable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/0001214659-26-002932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/d362618k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-26-002932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer